Thursday May 25th 2017

Posts Tagged ‘Brain’

TB vaccine may reduce symptoms and brain lesions of multiple sclerosis

TB vaccine may reduce symptoms and brain lesions of <b>multiple sclerosis</b>

TB vaccine may reduce symptoms and brain lesions of multiple sclerosis THIS STUDY involved 82 adults (average age, 32) at high risk for developing multiple sclerosis because they had had an episode involving numbness, vision problems or balance problems — such an event is [Read More]

Dr. Zamboni’s CCSVI Doppler Demonstration

Dr. Zamboni’s CCSVI Doppler Demonstration

CCSVI (Chronic Cerebrospinal Venous Insufficiency) in Multiple Sclerosis. This video demonstrates how blockage in the veins creates reflux of blood into the brain and spine. From the Bologna conference of September 8, 2009, sponsored by the Hilarescere Foundation Posted by [Read More]

Latest Topics

MS Study Alert: Share Your Thoughts About MS Research

MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Immune diseases like multiple sclerosis and hemophagocytic lymphohistiocytosis unleash destructive waves of [Read More]

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of [Read More]